Prevalence and predictors of peripherally inserted central catheter-associated bloodstream infections in adults: A multicenter cohort study

Jae Hwan Lee1,2*, Eung Tae Kim3,4*, Dong Jae Shim5, Il Jung Kim6, Jong Hyun Byeon5, In Joon Lee1,2, Hyun Beom Kim1,2, Young Ju Choi2, Jin Hong Lee2

1 Center for Liver Cancer, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 2 National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 3 Department of Radiology, Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Republic of Korea, 4 Department of Radiology, College of Medicine, Kangwon National University, Chuncheon-si, Gangwon-do, Republic of Korea, 5 Department of Radiology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 6 Department of Radiology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

* Current address: Department of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea
* ket9818@hanmail.net

Abstract

Objective
To evaluate the prevalence and predictors of peripherally inserted central catheter-associated bloodstream infection (PBSI) and PBSI-related death in hospitalized adult patients.

Materials and methods
A retrospective multicenter cohort of consecutive patients who underwent PICC placement from October 2016 to September 2017 at four institutes was assembled. Using multivariable logistic and Cox-proportional hazards regression models, all risk factors were analyzed for their association with PBSI. Multivariable logistic models were used to evaluate predictors of PBSI-related death.

Results
During the study period, a total of 929 PICCs were inserted in 746 patients for a total of 17,913 catheter days. PBSI occurred in 58 patients (6.2%), with an infection rate of 3.23 per 1,000 catheter days. Number of catheter lumens [double lumen, odds ratio (OR) 5.295; 95% confidence interval (CI), 2.220–12.627; hazard ration (HR) 3.569; 95% CI, 1.461–8.717], PICC for chemotherapy (OR 4.94; 95% CI, 1.686–14.458; HR 7.635; 95% CI, 2.775–21.007), and hospital length of stay (OR 2.23; 95% CI, 1.234–4.049; HR 1.249; 95% CI, 0.659–2.368) were associated with PBSI. Risk factors, such as receiving chemotherapy (OR 54.911; 95% CI, 2.755–1094.326), presence of diabetes (OR 11.712; 95% CI, 1.513–
90.665), and advanced age (OR 1.116; 95% CI 1.007–1.238), were correlated with PBSI-related death.

Conclusion

Our results indicated that risk factors associated with PBSI included the number of catheter lumens, the use of PICCs for chemotherapy, and the hospital length of stay. Furthermore, PBSI-related death was common in patients undergoing chemotherapy, diabetics, and elderly patients.

Introduction

Peripherally inserted central catheters (PICCs) are increasingly used in contemporary medicine because of their characteristics of feasibility, accessibility, safety, versatility, and cost-effectiveness [1]. The growing use of PICCs also stems from the seeming superiority of PICCs to other central venous catheters with respect to risk of hospital-acquired bloodstream infection, which is an important and preventable cause of the morbidity and mortality in hospitalized patients [2, 3]. Possible reasons suggested for this lower risk of infection include the lower bacterial density and lower temperature of the PICC placement site compared with neck or groin placement sites of other central venous catheters [4]. However, recent data from hospitalized patients suggest that PICC-associated bloodstream infection (PBSI) rates vary among different patient settings and are actually comparable to blood stream infection rates of standard central venous catheters [1, 4, 5]. Other studies reveal that the PBSI rate is not lower than the central line-associated bloodstream infection (CLABSI) rate, which ranges from 0.6 to 7.4% for catheter days ranging from 0.07 to 2.46 per 1000 days [1, 3, 6–9]. These studies also show that the occurrence of CLABSI is more frequent in patients with intensive care unit (ICU) stays and patients with hematologic malignancies [1, 6–9]. These varying data raise the question of whether PICCs are truly safer than central venous catheters with respect to catheter-associated bloodstream infections. Despite several reports regarding risk factors of PBSI in single centers or among oncologic patients [6–8], there has been no investigation evaluating prevalence and predictors of PBSI in varied patient care environments that reflect the real-world situation. Given the important role of CLABSI in patient mortality [10], there is a surprising paucity of data to specifically identify predictors of PBSI-related death. To better inform clinicians regarding PICC use and improve patient safety, the factors associated with adverse clinical outcome must be elucidated. Consequently, the purpose of this study was to evaluate the prevalence and predictors of PBSI and PBSI-related death in hospitalized adult patients.

Materials and methods

Study design and data collection

This was a multicenter retrospective cohort study conducted in four hospitals, including two tertiary institutions, a single secondary institution, and a national cancer center hospital. Briefly, Incheon St. Mary’s Hospital and Bucheon St. Mary’s Hospital are 901- and 613-bed tertiary general hospital, respectively. Hanyang University Guri Hospital are 578-bed secondary general hospital respectively. National cancer center hospital are 555-bed secondary cancer hospital respectively. All participating hospitals are teaching hospitals and located in urban area. The institutional review boards of each site (CMC-IRB, NCC-IRB, HY Guri-IRB)
approved this study, and informed patient consent was waived. Medical records of consecutive adult inpatients receiving PICC between October 2016 and September 2017 at each site were collected. Patients were excluded if they transferred early, had short indwelling times (<2 days), or lacked information regarding the insertion or removal date of PICC (Fig 1). Therefore, hospitalized patients more than 2 days were included.

**PICC insertion and management**

All participating institutions followed the Korean Nosocomial Infection Surveillance and Prevention Protocol [11] and United States guidelines for preventing catheter-related infections [12]. In brief, maximal sterile barrier precautions with skin decontamination using iodine tincture or 2% chlorhexidine gluconate were applied before PICC placement. Single or dual 4–6 French (Fr) lumen catheters (PowerPICC, Bard Access Systems Inc., Salt Lake City, UT, USA; Turbo-Ject PICC, Cook Medical, Bloomington, IN, USA; Pro-PICC, Medical Components Inc., Harleysville, PA, USA) were used in our study. All PICCs were inserted by trained interventional radiologists who followed the protocol of using the smallest caliber of PICC in the largest vein available. The procedure was performed in a dedicated angiography suite or at bedside in cases of some ICU patients. Each procedure was done using ultrasonography and fluoroscopy guidance, followed a maximal evidence-based institutional aseptic protocol. All percutaneous access was performed with ultrasonography at the upper arm. The upper arm was the preferred location to insert PICCs unless there were clinical contraindications (e.g., previous axillary operation or radiotherapy, arm edema, or arteriovenous fistula for dialysis access). At the end of the procedure, the catheter tip location was assessed by fluoroscopy or plain radiography to determine if it was placed at the cavoatrial junction. Regular device checks took place according to the protocol of each institution. Insertion-site care entailed weekly changes of transparent, semi-permeable film-covered dressing and new sterile gauze application every other day in all hospitals.

**Definition and variables**

The National Healthcare Safety Network surveillance definition of PBSI was used [13]. In brief, PBSI is a primary bloodstream infection in a patient who has had a PICC in place for >2
days and has a recognized pathogen (identified from one or more blood specimens by a culture- or non-culture-based microbiologic test) that is not related to an infection at another site. If laboratory studies failed to identify causative bacteria, the case was not identified as PBSI to reduce potential selection bias among different hospital environments. The prevalence of PBSI was calculated as percentage and rate per catheter day [8].

A patient death was defined as related to PBSI when systemic bacteremia from a PBSI existed prior to the patient’s death and the cause of death was assumed to be due to the progression of PBSI-related sepsis [10]. Death certificates of all cases of deceased patients were reviewed to identify the cause of death. Patients with other causes of death, such as aggravation of underlying disease or infection other than PBSI, were excluded. All medical records of potential PBSI or PBSI-related death cases were reviewed manually to confirm whether they met the PBSI definition.

Variables regarding PICC use were analyzed using a conceptual model of predictors of PICC complication [7]. In brief, this model consists of patient, device, and provider factors that could influence PICC-related complications. The ICU status was defined as patients who required any ICU care during hospitalization. The indication of PICC placement was based on initial purpose of catheterization, such as venous access and hydration, parenteral nutrition, antibiotics delivery, or chemotherapy. Dwell time of PICCs was calculated in days by subtracting the date of removal from the date of PICC insertion. Two reviewers adjudicated these data to ensure agreement on assignment.

**Statistical analysis**

The unit of all statistical analyses was each PICC insertion. Mixed-effects binary logistic regression was used to predict PBSI and PBSI-related death, adjusting for patient-, device-, and provider-level characteristics. Predictors of PBSI and PBSI-related death were evaluated first by univariable tests, and then by using a full multivariable model including variables with \( p \) values < 0.20. Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for ‘time to infection’ of PBSI. Statistical significance was set at \( p < 0.05 \). SPSS for Windows (v18.0; SPSS Inc., Chicago, IL, USA) and Stata MP SE (StataCorp, College Station, TX, USA) were used for analyses.

**Results**

Between October 2016 and September 2017, 929 PICCs were placed in 746 individual patients, resulting 17,913 catheter days. Nearly half of the patients had malignant solid tumors (n = 514; 55.4%). The most common indications for PICC insertion were intravenous infusion (56.6%; n = 526), antibiotics therapy (23.5%; n = 218), total parenteral nutrition (TPN; 16.0%; n = 149), and delivery of chemotherapy (3.8%; n = 35). Almost two thirds of catheters were double-lumen devices (62.7%; n = 592), which represents a device-related factor. With respect to provider characteristics, the majority of catheters were placed in the patient’s right upper arm (65.7%, n = 610; Table 1).

Among 929 PICCs evaluated in our analysis, 58 (6.2%) developed PBSI over 1366 catheter days, corresponding to 3.23 per 1000 catheter days. With respect to microbiology, coagulase negative *staphylococci* (44.8%), *staphylococcus aureus* (17.2%), *Candida* species (6.9%), and *Escherichia coli* (6.8%) account for most of the causative bacteria (Table 2).

Univariable analysis indicated PBSI was associated with patients who had PICC placement in the left arm for antibiotic therapy and with chemotherapy. Importantly, PBSI was strongly associated with number of catheter lumens, with double lumen catheters presenting a greater risk than a single lumen catheter. Multivariable model analysis revealed that patients receiving
PICCs for chemotherapy, hospital length of stay, and the number of catheter lumens were significant predictors for PBSI (Table 3). Specifically, PICCs with double lumens showed greater risk (OR 5.295; 95% CI, 2.220–12.627) than the other predictors. The HRs of patients receiving PICCs for chemotherapy were higher than the ORs, suggesting that an indication for chemotherapy was associated not only with PBSI but also earlier time to infection (OR 4.937; 95% CI 1.686–14.458, HR 7.635; 95% CI 2.775–21.007).

A total of 45 patients died during the study period. Among them, six patients (13.4%) were confirmed as having a PBSI-related death. Univariable and multivariable analyses for predictors of PBSI-related death showed that use of PICCs for chemotherapy, type II diabetes, and advanced age were factors associated with PBSI-related death (Table 4). The mean age of patients who suffered PBSI-related death was significantly older than that of the other patients.

Table 1. Descriptive statistics for patient, device, and provider predictors of PBSI according to PBSI status.

| Predictor | Total (n = 929) | Non-PBSI (n = 871) | PBSI (n = 58) | p value |
|-----------|----------------|-------------------|--------------|---------|
| **Patient-Related** | | | | |
| Mean age ± SD (yr) | 66.6±15.5 | 66.5±15.5 | 67.8±15.1 | 0.511 |
| Gender (Male) | 428 (46.1) | 400 (45.9) | 28 (48.3) | 0.068 |
| **Comorbidities** | | | | |
| None | 246 (26.5) | 230 (26.4) | 16 (27.6) | Ref |
| Diabetes mellitus (type II) | 141 (15.2) | 127 (14.6) | 14 (24.1) | 0.177 |
| Malignant solid tumor | 514 (55.3) | 487 (55.9) | 26 (44.8) | 0.416 |
| Hematologic malignancy or neutropenia (ANC<500) | 36 (3.7) | 34 (3.9) | 2 (3.4) | 0.858 |
| Multicomorbidity (>2) | 7 (0.7) | 7 (0.7) | 0 (0) | - |
| Intensive care unit stay (days) | 134 (14.4) | 122 (14.0) | 12 (20.7) | 0.175 |
| Presence of additional intravascular device | 52 (5.6) | 47 (5.4) | 5 (8.6) | 0.367 |
| Hospital length of stay (days) | 45.9 [2–839]* | 44.9 [2–839]* | 61.4 [13–210]* | 0.073 |
| **Indication** | | | | |
| Intravenous infusion | 526 (56.6) | 501 (57.5) | 25 (43.1) | Ref |
| TPN | 149 (16.0) | 141 (16.2) | 7 (12.1) | 0.991 |
| Antibiotics therapy | 218 (23.5) | 197 (22.6) | 21 (36.2) | 0.014 |
| Chemotherapy | 35 (3.8) | 31 (3.4) | 5 (8.6) | 0.022 |
| Dwell time (days) | 20.4 [2–239]* | 20.3 [2–239]* | 23.5 [3–84]* | 0.006 |
| **Device-Related** | | | | |
| Lumens | | | | |
| Single | 337 (36.3) | 331 (38.0) | 6 (10.3) | Ref |
| Double | 592 (62.7) | 540 (62.0) | 52 (89.7) | <0.001 |
| **Provider-Related** | | | | |
| Arm | | | | |
| Right | 610 (65.7) | 564 (64.8) | 46 (79.3) | 0.027 |
| Vein | | | | |
| Basilic | 616 (66.3) | 576 (66.1) | 40 (69.0) | Ref |
| Brachial | 257 (27.7) | 242 (27.8) | 15 (25.9) | 0.716 |
| Cephalic | 56 (6.0) | 53 (6.1) | 3 (5.2) | 0.740 |

Note: Unless otherwise indicated, data are expressed as numbers of patients. Numbers in parenthesis are percentages. Key: (PBSI) peripherally inserted central catheter-associated bloodstream infection, (ANC) absolute neutrophil count; (TPN) total parenteral nutrition (*') mean [range].

https://doi.org/10.1371/journal.pone.0213555.t001
We found no association between device or provider factors and risk of PBSI-related death.

**Discussion**

In this study, PBSI occurred in 6.2% of patients with total PICC insertion, resulting in an infection rate of 3.23 per 1,000 catheter days. This PBSI rate is higher than that previously reported in single-center studies, which may be due to the heterogeneous patient groups and patient-
One of the hospitals in the multicenter cohort is a national cancer center whose patients primarily had active cancer, and more than half of the patients in our study population had a solid or hematologic malignancy. Moreover, our study only enrolled hospitalized patients who were by definition more susceptible to hospital-acquired infections than outpatients. These results provided a more realistic overview of PICC management in daily practice.

Our results also showed that the use of PICC for chemotherapy was not only associated with PBSI but may also accelerate the development of PBSI. Previous reports show that chemotherapy plays an important role in PBSI occurrence in hospitalized patients, probably due to immunosuppression by various chemotherapy drugs that make the patient vulnerable to infection [8]. These reports emphasize the importance of PICC management in susceptible patients. Interestingly, in contrast to a previous study (6), PBSI was not associated with patients with hematologic malignancy or neutropenia in our study. This discrepancy might be due to the very low patient population (n = 36, 3.7%) of hematologic malignancy or neutropenia in our study, which limited statistical evaluation.

Increasing the number of the catheter lumen was strongly associated with the development of PBSI. This result is similar to a previous study that found an increasing order of PBSI risk associated with double- to triple-lumen catheters (HR 4.08 and 8.52, respectively) [7].

| Predictor | Univariable analysis | Multivariable analysis |
|-----------|----------------------|-----------------------|
|           | OR (95% CI)          | p value               | OR (95% CI)          | p value               |
| **Patient-Related** | | | | |
| Mean age  | 1.091 (1.004–1.185)  | 0.039                 | 1.115 (1.006–1.235)  | 0.038                 |
| Gender (Male/Female) | 1.172 (0.235–5.836)  | 0.847                 | | |
| **Comorbidities** | | | | |
| None      | 1 (ref.)             | 0.995                 | | |
| Diabetes mellitus (type II) | 11.474 (2.081–63.255) | 0.005               | 11.828 (1.537–91.030) | 0.018               |
| Malignant solid tumor | 2.491 (0.454–13.670)  | 0.293                 | | |
| Hematologic malignancy or neutropenia (ANC<500) | 1.092 (0.000–1.007)  | 0.998                 | | |
| Intensive care unit stay (d) | 2.996 (0.543–16.522)  | 0.208                 | | |
| Presence of additional intravascular device | 1.092 (0.000–1.011)  | 0.998                 | | |
| Hospital length of stay (d) | 0.999 (0.985–1.013)  | 0.916                 | | |
| **Indication** | | | | |
| Intravenous infusion or TPN | 1 (ref.) | Ref. | 1 (ref.) | Ref. |
| Antibiotics therapy | 4.667 (0.775–28.112)  | 0.159                 | 2.621 (0.405–16.950)  | 0.312               |
| Chemotherapy | 9.882 (0.874–111.699) | 0.064               | 68.044 (3.426–1351.444) | 0.006               |
| Dwell time (d) | 0.985 (0.932–1.041)  | 0.596                 | | |
| **Device-Related** | | | | |
| Lumens (double/single) | 1.139 (0.208–6.254)  | 0.881                 | | |
| **Provider-Related** | | | | |
| Arm (right/left) | 0.000 | 0.994 | | |
| Vein | | | | |
| Basilic | 1 (ref.) | 0.797 | | |
| Brachial | 0.477 (0.055–4.106)  | 0.501                 | | |
| Cephalic | 0.000 | 0.998 | | |

Key: (PBSI) peripherally inserted central catheter-associated bloodstream infection; (OR) odds ratio; (CI) confidence interval; (ANC) absolute neutrophil count; (TPN) total parenteral nutrition; (N/A) not applicable.

https://doi.org/10.1371/journal.pone.0213555.t004
possible explanation for these results might be that increased manipulation of the catheter hub and catheter surface area augments bacterial translocation and migration to systemic blood circulation.

Consistent with a previous study [7], our results showed that hospital length of stay, rather than the catheter dwell time, increased the risk of PBSI. We speculate that a longer hospital stay reflects the severity of a patient’s illness and increases the chance of hospital-acquired infections.

PBSI-related death was associated with old age, diabetes, and receiving chemotherapy. Although a previous study [10] suggests that CLABSI is associated with an increased risk of death, there has been a paucity of data to directly reveal predictors of PBSI-related death. Interestingly, the prevalence of PBSI was strongly associated with device factor, whereas risk of PBSI-related death was associated only with patient factor. We postulate that when PBSI occurs, susceptible patients are at an increased risk of death. This explanation supports the need for meticulous care for patients with PICCs, such as using single rather than multiple lumen catheters in high-risk patients to decrease the incidence of PBSI and PBSI-associated mortality.

The present study has several limitations. First, the retrospective design of our study is subject to selection bias. To minimize bias and enhance generalizability, we performed concurrent analyses of all consecutive patients at the different multicenter settings. Second, all PICC insertions in our study were performed by interventional radiologists. A previous study has suggested that a provider factor can influence the clinical outcome of PBSI [7]. However, we were unable to test that aspect because of a lack of venous access nursing teams to perform PICC insertions in the participating institutions. Third, we did not find any association between catheter dwell time and PBSI, possibly because PICCs were often removed without microbiological confirmation when PICC-related infection was clinically suspected. Fourth, there was a relatively small number of PICC-related death in this study, so that statistical significance of variables regarding PBSI-related death might be exaggerated. However old age, the presence of diabetes, and PICC use for chemotherapy could be regarded as clinically relevant factors to explain PBSI-related death. Further study with prospective design is needed for precise evaluation of PBSI-related death.

In conclusion, PBSI was associated with the number of catheter lumens, the use of PICC for chemotherapy, and the hospital length of stay. PBSI-related deaths were common in patients receiving chemotherapy, type II diabetics, and elderly patients. Full data set of present study is on S1 Table.

Supporting information
S1 Table. Full data set of present study.
(XLSX)

Acknowledgments
We thank Pyunghwa Kim for editorial assistance.

Author Contributions
Conceptualization: Dong Jae Shim, Il Jung Kim, Jong Hyun Byeon, In Joon Lee.
Data curation: Jae Hwan Lee, Eung Tae Kim, Il Jung Kim, Jong Hyun Byeon, Young Ju Choi, Jin Hong Lee.
Formal analysis: Jae Hwan Lee, Eung Tae Kim, Il Jung Kim.
Funding acquisition: Dong Jae Shim.
Investigation: Jae Hwan Lee, Eung Tae Kim, Dong Jae Shim, Il Jung Kim, Jong Hyun Byeon.
Methodology: Dong Jae Shim, Jong Hyun Byeon.
Resources: Eung Tae Kim, Dong Jae Shim, Jong Hyun Byeon, Young Ju Choi, Jin Hong Lee.
Supervision: Il Jung Kim, In Joon Lee, Hyun Beom Kim.
Validation: Jong Hyun Byeon, In Joon Lee.
Writing – original draft: Jae Hwan Lee, Eung Tae Kim, Dong Jae Shim.
Writing – review & editing: Jae Hwan Lee, Eung Tae Kim, Dong Jae Shim, In Joon Lee, Hyun Beom Kim.

References
1. Chopra V, O’horo JC, Rogers MA, Maki DG, Safdar N. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. Infection Control & Hospital Epidemiology. 2013; 34(9):908–18.
2. Maki DG, Kluger DM, Cnrich CJ, editors. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clinic Proceedings; 2006: Elsevier.
3. Gunst M, Matsushima K, Vanek S, Gunst R, Shafi S, Frankel H. Peripherally inserted central catheters may lower the incidence of catheter-related bloodstream infections in patients in surgical intensive care units. Surgical infections. 2011; 12(4):279–82. https://doi.org/10.1089/sur.2008.058 PMID: 20629557
4. Safdar N, Maki DG. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients. Chest. 2005; 128(2):489–95. https://doi.org/10.1378/chest.128.2.489 PMID: 16100130
5. Ajenjo MC, Morley JC, Russo AJ, McMullen KM, Robinson C, Williams RC, et al. Peripherally inserted central venous catheter–associated bloodstream infections in hospitalized adult patients. Infection Control & Hospital Epidemiology. 2011; 32(2):125–30.
6. Walshie LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. Journal of Clinical Oncology. 2002; 20(15):3276–81. https://doi.org/10.1200/JCO.2002.11.135 PMID: 12149302
7. Chopra V, Ratz D, Kuhn L, Lopus T, Chenoweth C, Krein S. PICC-associated bloodstream infections: prevalence, patterns, and predictors. The American journal of medicine. 2014; 127(4):319–28. https://doi.org/10.1016/j.amjmed.2014.01.001 PMID: 24440542
8. Bouzad C, Duron S, Bousquet A, Arnaud F-X, Valbousquet L, Weber-Donat G, et al. Peripherally inserted central catheter–related infections in a cohort of hospitalized adult patients. Cardiovascular and Interventional Radiology. 2016; 39(3):385–93. https://doi.org/10.1007/s00270-015-1182-4 PMID: 26202391
9. McDermid S, Scrivens N, Carrier M, Sabri E, Toy B, Huebsch L, et al. Outcomes in a nurse-led peripherally inserted central catheter program: a retrospective cohort study. CMAJ open. 2017; 5(3):E535. https://doi.org/10.9778/cmajo.201700010 PMID: 28676535
10. Ziegler MJ, Pellegrini DC, Safdar N. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis. Infection. 2015; 43(1):29–36. https://doi.org/10.1007/s15010-014-0689-y PMID: 25331552
11. Choi YH. Prospective nationwide healthcare-associated infection surveillance system in South Korea. Journal of the Korean Medical Association. 2018; 61(1):21–5.
12. O'grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clinical infectious diseases. 2011; 52(9):e162–e93. https://doi.org/10.1093/cid/cir257 PMID: 21460264
13. Tedja R, Gordon SM, Fatica C, Fraser TG. The descriptive epidemiology of central line-associated bloodstream infection among patients in non-intensive care unit settings. Infect Control Hosp Epidemiol. 2014; 35(2):164–8. Epub 2014/01/21. https://doi.org/10.1086/674856 PMID: 24442079